October 22, 2020 Drug Utilization Review Board
»
1. Call to order
1. Call to order
»
2. Announcement: October DURB two-day meeting process
2. Announcement: October DURB two-day meeting process
»
3. Public comment on the new drug classes to be reviewed for the Medicaid Preferred Drug List (PDL): » - a. Anticonvulsants b. Hemophilia treatment – (i.e., antihemophilic) c. HIV /AIDS (i.e., antiretroviral) d. Multiple sclerosis agents e. Oncology, oral – Breast (i.e., antineoplastic) f. Oncology, oral – Hematologic (i.e., antineoplastic) g. Oncology, oral – Lung (i.e., antineoplastic) h. Oncology, oral – Other (i.e., antineoplastic) i. Oncology, oral – Prostate (i.e., antineoplastic) j. Oncology, oral – Renal cell (i.e., antineoplastic) k. Oncology, oral – Skin (i.e., antineoplastic)
3. Public comment on the new drug classes to be reviewed for the Medicaid Preferred Drug List (PDL): »
a. Anticonvulsants b. Hemophilia treatment – (i.e., antihemophilic)
c. HIV /AIDS (i.e., antiretroviral)
d. Multiple sclerosis agents
e. Oncology, oral – Breast (i.e., antineoplastic)
f. Oncology, oral – Hematologic (i.e., antineoplastic)
g. Oncology, oral – Lung (i.e., antineoplastic)
h. Oncology, oral – Other (i.e., antineoplastic)
i. Oncology, oral – Prostate (i.e., antineoplastic)
j. Oncology, oral – Renal cell (i.e., antineoplastic)
k. Oncology, oral – Skin (i.e., antineoplastic)
»
Items 4 & 5 » - 4. Therapeutic and clinical drug reviews and updates: Magellan Medicaid Administration 5. Adjourn – Day One
Items 4 & 5 »
4. Therapeutic and clinical drug reviews and updates: Magellan Medicaid Administration 5. Adjourn – Day One
